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A FTER whole organ pancreas transplantation with duo-denojejunostomy to drain the exocrine secretions was 
reintroduced in 1984,1 a few centers adopted this technique 
to replace transplantation of the body and tail of the 
pancreas, which had been the procedure of choice in the 
1970s and early 1980s. Although in the early clinical trials 
using cyclosporine in whole organ pancreas transplantation, 
the incidence of thrombosis appeared to be less than with 
transplantation of the tailor "pancreatic segment," it was by 
no means insignificant, and it was considered that cyclospo-
rine, given its vasoconstrictive properties, might be a con-
tributing factor. l However, there were other reasons why 
the pancreas was more prone to thrombosis than either the 
kidney or the liver, in both of which there is a much higher 
blood flow by comparison with the pancreas. These factors 
include twisting or compression of the portal vein, ischemic 
injury, pancreatitis, and reperfusion injury. In addition, 
acute rejection played a role in early pancreas allograft loss. 
Therefore, it was believed that if a lower dose of cyclo-
sporine (or no cyclosporine at all) was used in combination 
with an anti-T cell antibody administered during the first 10 
days following transplantation, the incidence of acute rejec-
tion and thrombosis would be reduced. Most pancreas 
transplant centers in the United States and Europe adopted 
this immunosuppression regimen with delayed introduction 
of cyclosporine. the so-called "quadruple sequential immu-
nosuppressive therapy," introduced by Sollinger.3 
In the late 1980s and 1990s, both patient and graft 
survival improved with this regimen. probably more as a 
result of technical refinements and a more restrictive policy 
of donor and recipient selection. than improvement in 
immunosuppression. In spite of these better results, surgi-
cally-related morbidity remained high,4 but this phenome-
non was not related to the choice of immunosuppressive 
regimen. 
By mid-1995, experience had been gained in a few centers 
using tacrolimus-based immunosuppression in pancreas 
transplantation. and a multicenter analysis was presented in 
a preliminary fashion in 1996 by Gruessner,5 and again, 
with more complete data and greater patient accrual in 
1997 at the annual meeting of the American Society of 
Transplant Surgeons (ASTS)." All of the contributing cen-
ters but one (Pittsburgh) used tacrolimus in combination 
with antibody induction. Results of the retrospective mul-
ticenter analysis. presented by Gruessner. showed a 1 year 
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patient and graft survival of 97% and 85%. respectively.6 
Although the Pittsburgh group, which did not use anti 
T-cell induction therapy, contributed more patients than 
each of the other centers, except the University of Minne-
sota, in the multicenter retrospective analysis, the majority 
of the patients in the study had received antibody induction. 
Graft success rates were better with tacrolimus-based im-
munosuppression than with other drug regimens. In addi-
tion, graft survival improved substantially with tacrolimus in 
patients receiving a pancreas without a kidney, ie, pancreas 
after kidney transplantation (P AK) and pancreas transplant 
alone (PTA).6.7 However, these "solitary" graft recipients 
also received anti T-cell induction therapy in addition to 
tacrolimus. 
Although the data clearly showed that tacrolimus was 
superior to cyclosporine, it was difficult to conclude in a 
definitive fashion that the addition of an anti-T-cell prepa-
ration in combination with tacrolimus was necessary. 
THE PITTSBURGH DATA 
During a 3-year period, July 1994 through July 1997. 123 patients 
received pancreas transplants. 104 in combination with a kidney 
from the same donor (simultaneous pancreas kidney [SPK)). One 
year actuarial patient. kidney and pancreas survival (Kaplan-
Meier) was 98%, 95%. and 83%. respectively. One patient. who 
was highly sensitized and whose Iymphocytoxic cross-match turned 
positive at 3 days, lost both grafts. Five other patients lost pancreas 
function at 3. 6. 9, 11. and 11 months. 2 had recurrent pancreatitis. 
and 3 had chronic rejection. All other losses were a result of other 
factors including early graft thrombosis (largely from high-risk 
donors), surgical complications. pancreatitis. and death in one 
patient from disseminated lymphoma with normal graft function. 
Rejection episodes occurred in 64% of the patients which 
reversed with steroid therapy, except in 9 patients (7%) who 
responded to antibody treatment. Only 2 uf the last 80 patients. 
who also received mycophenolate mllfetil. required anti-T cell 
antibody. 
While it is not the intent of this presentation to detail the 
prescription for preventing and managing surgical complication-
related graft loss. which is presented elsewhere." it is important to 
note that. as the program matured. these types of graft losses were 
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minimal. The important point here is that only one pancreas was 
lost to early rejection (antibody-mediated), which could not have 
been prevented by any immunosuppressive regimen with or with-
out anti-T cell induction. It is also possible that in the two graft 
losses to recurrent pancreatitis (bladder-drained), chronic rejection 
may have played a role. However, no pancreases were lost within 
the first year to acute cellular rejection. Of even greater signifi-
cance. is the fact that only 5 kidneys, transplanted from the same 
donors, were lost within the first year, 2 to sepsis following 
discontinuation of immunosuppressive agents, 1 death to posttrans-
plant Iymphoproliferative disorder with normal renal and pancre-
atic function, 1 to hyperacute rejection, and 1 to arterial thrombo-
sis, but none from acute rejection. 
Although a positive pp 65 CMV antigen was observed in many of 
the cytomegalovirus (CMV) seronegative patients who received 
organs from seropositive donors. only one patient was hospitalized 
with a febrile illness for 1 week without pulmonary or liver disease. 
A few of the seropositive to seronegative patients were given 
prophylatic Ganciclovir during the early part of the program. but 
the majority of these patients were not given prophylaxis for CMV. 
All seronegative recipients who had received seropositive donors 
were tested weekly for pp 65 CMV antigen, and if the test turned 
positive. were treated with a course of Ganciclovir predominately 
as an out patient, for 2 weeks or longer until the pp 65 antigen was 
undetectable. The association of CMV disease and the use of 
anti-T cell antibodies, either monoclonal or polyclonal, is well 
recognized, and it is clear from this series of over a 120 patients, in 
whom an anti-T cell agent was not used prophylactically, that the 
incidence of clinically significant CMV disease was low. 
DISCUSSION 
Whether anti T-cell induction therapy played a role in 
preventing graft loss from cyclosporine treated pancreas 
transplant recipients cannot be stated definitively. However, 
even in our first series of 20 SPK patients, treated with 
cyclosporine, azathioprine and prednisone performed more 
than a decade ago, pancreas graft loss to acute rejection 
occurred in only one patient within the first year. 9 In the 
current Pittsburgh series, graft loss to rejection was mini-
mal. JO 
Adequate blood trough levels of tacrolimus are required, 
particularly within the first 2 to 3 months after transplanta-
tion. Patients are given intravenous tacrolimus 0.05 mg/kg 
for 5 to 7 days followed by an initial oral dose of 0.15 mg/kg 
twice a day. The dose is adjusted daily to achieve whole 
blood trough levels of 20 to 25 ng/mL for the first 2 weeks. 
15 to 20 ng/mL by one month. 10 to 15 ng/mL by 3 months, 
and 7 to 12 ng/mL chronically. Patients received either 
azathaprine or mycophenolate mofetil (the latter in the 
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second half of the Pittsburgh series) as well as tapering 
steroid doses, which were withdrawn in about a third of the 
patients between 6 months and 1 year. The use of intrave-
nous tacrolimus for the first 5 to 7 days was well tolerated, 
with little drug toxicity. Only one patient had significant 
neurological symptoms, and one required hemodialysis 
postoperatively which was related to acute tubular necrosis. 
A few had hyperglycemia, which recovered after reduction 
in both the tacrolimus and prednisone dosages. The impor-
tance of achieving adequate target blood levels of tacroli-
mus, particularly during the first few months, together with 
an appropriate tapering strategy as outlined above, should 
be underscored. To achieve these optimal target trough 
blood levels, the actual dose of tacrolimus varied widely 
from patient to patient. 
In conclusion, the use of tacrolimus without anti-T cell 
preparations for induction in pancreas transplantation is 
largely limited to the Pittsburgh data, which confirms the 
fact that antibody induction is not necessary to prevent 
acute rejection-related graft loss. Furthermore, the inci-
dence of clinical CMV disease is low in this series, a 
potential benefit of avoiding the use of prophylactic or 
induction anti T-cell antibody drug therapy. Whether either 
mycophenolate mofetil or azathioprine is necessary as a 
third drug has not been addressed, but the requirement for 
anti-T cell antibody for refractory rejection was less when 
mycophenolate mofetil was used. 
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